You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 4, April 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Epidemiology
 This Article
 •Full text
 •PDF
 •CME Course for This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Women's Health
 •Menopause
 •Macular Degeneration
 •Aging/ Geriatrics
 •Alert me on articles by topic

Menopausal and Reproductive Factors and Risk of Age-Related Macular Degeneration

Diane Feskanich, ScD; Eunyoung Cho, ScD; Debra A. Schaumberg, ScD, OD, MPH; Graham A. Colditz, MD, DrPH; Susan E. Hankinson, ScD

Arch Ophthalmol. 2008;126(4):519-524.

Objective  To investigate whether estrogen exposures are associated with lower risks of age-related macular degeneration (AMD).

Methods  Postmenopausal hormone (PMH) use, past use of oral contraceptives (OCs), ages at menarche and menopause, and parity were assessed among 74 996 postmenopausal women. Over 22 years, cases of early (n = 554) and neovascular (n = 334) AMD with a visual acuity of 20/30 or worse were identified. Cox models were used to calculate the relative risk for each exposure, adjusted for smoking and other factors.

Results  Current PMH users had a notable 48% lower risk of neovascular AMD compared with those who had never used PMH, although risk did not decline linearly with longer durations of use. Risk was lowest for PMH users who had used OCs in the past (P value for interaction, .03). In contrast, risk of early AMD was a notable 34% higher among current PMH users and OC use was unassociated with risk. The only remarkable finding for the endogenous estrogenic factors was a 26% lower risk of early AMD for parous women.

Conclusions  Although PMH and OC use were associated with a lower risk of neovascular AMD, no benefit was observed for early AMD. Factors influencing lifetime exposure to estrogens were not consistently associated with the disease.


Author Affiliations: Channing Laboratory, Department of Medicine (Drs Feskanich, Cho, Colditz, and Hankinson) and Division of Preventive Medicine (Dr Schaumberg), Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Department of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, Boston (Dr Schaumberg); and Department of Epidemiology, Harvard School of Public Health, Boston (Drs Colditz and Hankinson).







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.